| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2134326 | Experimental Hematology | 2009 | 14 Pages |
Abstract
These findings suggest that targeted disruption of key signaling pathways in combination with the tyrosine kinase activity of leukemic oncogenes, such as Tel/PDGFRβ, may result in more efficacious therapies for suppressing leukemic progression in the clinical setting.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Edwina Dobbin, Ciaren Graham, Pamela M. Corrigan, Keith G. Thomas, Robin W. Freeburn, Helen Wheadon,